On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

(2017) J.S. Weber et al.   ANNALS OF ONCOLOGY

Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).

(2017) T. J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

(2014) C. Lebbe et al.   ANNALS OF ONCOLOGY

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

CD28z CARs and Armored CARs

(2014) Hollie J. Pegram et al.   CANCER JOURNAL

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges

(2014) Siwen Hu-Lieskovan et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells

(2014) Y. Burmeister et al.   JOURNAL OF IMMUNOLOGY

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

(2014) Emanuela Romano et al.   Journal of Translational Medicine

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

(2014) E. Cha et al.   Science Translational Medicine

The TNF family in T cell differentiation and function – Unanswered questions and future directions

(2014) Michael Croft   SEMINARS IN IMMUNOLOGY

Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

(2014) S. Kitano et al.   Cancer Immunology Research

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy

(2014) Antonio M Grimaldi et al.   OncoImmunology

Trial Watch

(2014) Erika Vacchelli et al.   OncoImmunology

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

(2014) David A Schaer et al.   Journal for ImmunoTherapy of Cancer

Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?

(2013) Elizabeth Tranter et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Checkpoint blocking antibodies in cancer immunotherapy

(2013) Chrisann Kyi et al.   FEBS LETTERS

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift

(2013) Silvia C. Formenti et al.   JNCI-Journal of the National Cancer Institute

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Case 21-2013

(2013) Ryan J. Sullivan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

(2013) C. A. Barker et al.   Cancer Immunology Research

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer

(2013) E. B. Golden et al.   Cancer Immunology Research

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

(2013) Robert H. Vonderheide et al.   OncoImmunology

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

(2012) J. Wolchok   ANNALS OF ONCOLOGY

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

(2012) A. Juszczak et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

(2012) Andrea Wang-Gillam et al.   INVESTIGATIONAL NEW DRUGS

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

(2012) Andres Forero-Torres et al.   LEUKEMIA & LYMPHOMA

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

(2012) Stephanie Andrews et al.   Cancer Management and Research

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma

(2011) T. S. Lewis et al.   CLINICAL CANCER RESEARCH

Response to “Ipilimumab (Yervoy) and the TGN1412 catastrophe”

(2011) Michael A. Curran et al.   IMMUNOBIOLOGY

Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

(2011) Michela Maur et al.   JOURNAL OF CLINICAL ONCOLOGY

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum

(2011) S. C. Bendall et al.   SCIENCE

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

(2010) T. Nakahara et al.   BLOOD

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

(2010) M. Hussein et al.   HAEMATOLOGICA

T-cell exhaustion: characteristics, causes and conversion

(2010) John S. Yi et al.   IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

(2010) Chrystelle Brignone et al.   Journal of Translational Medicine

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia

(2010) Richard R. Furman et al.   LEUKEMIA & LYMPHOMA

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

(2010) Margaret K. Callahan et al.   SEMINARS IN ONCOLOGY

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

(2009) C. Brignone et al.   CLINICAL CANCER RESEARCH

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

(2009) Daniel Hirschhorn-Cymerman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

(2009) Katharina C. Kaehler et al.   MELANOMA RESEARCH

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

(2009) Troy Dillard et al.   Pituitary

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA